Two devices with ample data supporting their safety and efficacy in treating aneurysms – the WEB and FRED – and an ongoing commitment on the part of specialists and industry to continue to test them as they evolve. Join Christophe Cognard as he reviews two studies: with Laurent Spelle for the CLARYS study looking at the use of the WEB device in ruptured aneurysms; and the EuFRED study with Markus Möhlenbruch on the FRED flow-diverter.
What does CLARYS demonstrate about the efficacy of the WEB device in supplying a delayed thrombosis of the aneurysm? How does it the effect re-bleeding months after treatment? Understand the results, their implications along with the evolving size of the device itself. Discover the critical elements of this study and the clinical reasoning behind the protocol. Learn about the recently released primary outcome as well as the secondary endpoint of complications…and the future of WEB!
The EuFred study, a post-marketing study on the FRED flow-diverting device, is a large cohort study involving 15 high-volume European centers. With a low morbidity and mortality rate, understand how this compares to other studies and trials while exploring the possible reasons for these results. Learn about aneurysm location and size, the overall occlusion rates and follow-up results. Will this enlarge the indications for the FRED device beyond the ICA to the MCA? Enter the discussion today and find out now….
This interview was filmed at LINNC PARIS 2018
Silk Vista "Mama" 1st case experience
First US treatment of 3 patients with the FRED device after FDA approval